IN190508B - - Google Patents

Info

Publication number
IN190508B
IN190508B IN702CA1997A IN190508B IN 190508 B IN190508 B IN 190508B IN 702CA1997 A IN702CA1997 A IN 702CA1997A IN 190508 B IN190508 B IN 190508B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
David Morris Armistead
Michael Christopher Badia
Guy William Bemis
Randy Scott Bethiel
Catharine Armstrong Frank
Perry Michael Novak
Steven Michael Ronkin
Jeffrey Owen Saunders
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/636,361 external-priority patent/US5807876A/en
Priority claimed from US08/832,165 external-priority patent/US6054472A/en
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IN190508B publication Critical patent/IN190508B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
IN702CA1997 1996-04-23 1997-04-22 IN190508B (OSRAM)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/636,361 US5807876A (en) 1996-04-23 1996-04-23 Inhibitors of IMPDH enzyme
US08/801,780 US6344465B1 (en) 1996-04-23 1997-02-14 Inhibitors of IMPDH enzyme
US08/832,165 US6054472A (en) 1996-04-23 1997-04-02 Inhibitors of IMPDH enzyme

Publications (1)

Publication Number Publication Date
IN190508B true IN190508B (OSRAM) 2003-08-02

Family

ID=27417590

Family Applications (1)

Application Number Title Priority Date Filing Date
IN702CA1997 IN190508B (OSRAM) 1996-04-23 1997-04-22

Country Status (21)

Country Link
US (3) US6541496B1 (OSRAM)
EP (1) EP0902782A1 (OSRAM)
CN (2) CN1515248A (OSRAM)
AP (1) AP813A (OSRAM)
AU (1) AU723730B2 (OSRAM)
BG (1) BG64507B1 (OSRAM)
BR (1) BR9708735A (OSRAM)
CA (1) CA2252465C (OSRAM)
CZ (1) CZ298463B6 (OSRAM)
EA (1) EA004771B1 (OSRAM)
HU (1) HUP0004421A3 (OSRAM)
ID (1) ID16664A (OSRAM)
IL (1) IL126674A (OSRAM)
IN (1) IN190508B (OSRAM)
NO (1) NO312963B1 (OSRAM)
NZ (1) NZ332405A (OSRAM)
OA (1) OA10902A (OSRAM)
PL (1) PL192628B1 (OSRAM)
SK (1) SK286662B6 (OSRAM)
TR (1) TR199802136T2 (OSRAM)
WO (1) WO1997040028A1 (OSRAM)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133649C (zh) * 1996-10-18 2004-01-07 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3蛋白酶的抑制剂
WO1998024785A1 (en) * 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
EP1366766A1 (en) * 1997-03-14 2003-12-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
TR200001179T2 (tr) * 1997-10-31 2000-11-21 Aventis Pharma Ltd. Değiştirilmiş anilidler
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
DK1043995T3 (da) * 1997-12-22 2007-03-05 Bayer Pharmaceuticals Corp Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
JP4437270B2 (ja) * 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
AU3665199A (en) * 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
EP1085010B1 (en) * 1998-06-04 2004-03-10 Kumiai Chemical Industry Co., Ltd. Phenylacetylene derivatives and agricultural/horticultural bactericides
PL198852B1 (pl) * 1998-10-22 2008-07-31 Neurosearch As Podstawione pochodne fenylu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
AU1707700A (en) 1998-10-29 2000-05-22 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
US6420403B1 (en) 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
EP1126843A4 (en) 1998-10-29 2005-06-15 Bristol Myers Squibb Co AMINO-CELL DERIVATIVE COMPOUNDS INHIBITORS OF ENZYME IMPDH
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
RU2233269C2 (ru) * 1998-11-02 2004-07-27 Авентис Фарма Лимитед Замещенные анилиды, фармацевтическая композиция и способ лечения
US6166028A (en) 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
JP2002531555A (ja) * 1998-12-09 2002-09-24 ワイス フェニレンジアミン基を含む、アルファ−メチルベンジル−含有の、ヘルペスウイルスのチオ尿素インヒビター
US6201013B1 (en) 1998-12-09 2001-03-13 American Home Products Corporation Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group
JP2002531545A (ja) * 1998-12-09 2002-09-24 ワイス ヘルペスウイルスのチオ尿素インヒビター
US6262090B1 (en) 1998-12-09 2001-07-17 American Home Products Corporation Aminopyridine-containing thiourea inhibitors of herpes viruses
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
AU1689600A (en) * 1998-12-22 2000-07-12 Mitsubishi Chemical Corporation Amide derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
HUP0202248A3 (en) * 1999-03-12 2006-06-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
CN1196687C (zh) * 1999-03-19 2005-04-13 沃泰克斯药物股份有限公司 Impdh酶抑制剂
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
WO2000073288A1 (en) * 1999-05-28 2000-12-07 Vertex Pharmaceuticals Incorporated Method for preparing 5-substituted oxazoles
US6107052A (en) * 1999-06-09 2000-08-22 Roche Diagnostics Corporation Enzymatic measurement of mycophenolic acid
CA2377278C (en) * 1999-06-25 2010-03-23 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of impdh
JP2001011059A (ja) * 1999-06-28 2001-01-16 Nippon Synthetic Chem Ind Co Ltd:The ５−（２−置換−４−ニトロフェニル）−オキサゾールの製造方法
JP2001011060A (ja) * 1999-06-28 2001-01-16 Nippon Synthetic Chem Ind Co Ltd:The 新規オキサゾール化合物及びその製造方法
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6867299B2 (en) 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
WO2001081340A2 (en) * 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6423849B1 (en) 2000-09-01 2002-07-23 The Nippon Synthetic Chemical Industry Co., Ltd. Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, novel oxazole compound, and process of preparing the same
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US6593362B2 (en) * 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
CA2475818C (en) 2002-02-11 2011-07-19 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
ES2425739T3 (es) 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
EP1402887A1 (en) * 2002-09-18 2004-03-31 Jerini AG New compounds for the inhibition of undesired cell proliferation and use thereof
CA2510006C (en) * 2002-12-06 2012-02-07 Vertex Pharmaceuticals Incorporated Compositions comprising a combination of diphenyl urea impdh inhibitors and apoptosis-inducing anti-cancer agents
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US7220768B2 (en) * 2003-02-11 2007-05-22 Wyeth Holdings Corp. Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus
DE602004011340T2 (de) 2003-05-20 2008-11-06 Bayer Healthcare Llc Diaryl-harnstoffe mit kinasehemmender wirkung
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
KR20060130027A (ko) 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의억제제
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7494660B2 (en) 2003-10-27 2009-02-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
CN1938332B (zh) 2004-02-04 2011-10-19 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
EP1568696A1 (en) * 2004-02-26 2005-08-31 4Sc Ag Compounds as inhibitors of cell proliferation and viral infections
US7317030B2 (en) 2004-02-26 2008-01-08 4Sc Ag Compounds as inhibitors of cell proliferation and viral infections
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
HRP20080608T3 (hr) 2004-08-12 2008-12-31 Pfizer Inc. Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze
JP2008514723A (ja) * 2004-10-01 2008-05-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
PL1858877T3 (pl) * 2005-01-14 2014-08-29 Gilead Connecticut Inc 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
ES2393741T3 (es) * 2005-01-14 2012-12-27 Gilead Connecticut, Inc. Ureas 1,3-diarilsustituidas como moduladores de la actividad quinasa
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
UA93673C2 (ru) 2005-03-07 2011-03-10 Баер Шеринг Фарма Акциенгезельшафт Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
US7777040B2 (en) * 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
BRPI0608602A2 (pt) 2005-05-09 2010-01-19 Vertex Pharma processos para a preparaÇço de urÉias de biarila e anÁlogos dos mesmos
WO2006122012A2 (en) * 2005-05-09 2006-11-16 Vertex Pharmaceuticals Incorporated Polymorphic forms of (s)- tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate
RU2441870C2 (ru) 2005-07-29 2012-02-10 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP5230415B2 (ja) 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大員環状阻害剤
DE602006019883D1 (de) 2005-07-29 2011-03-10 Medivir Ab Makrocyclische inhibitoren des hepatitis-c-virus
US8183277B2 (en) 2005-07-29 2012-05-22 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
RS52058B (sr) 2005-07-29 2012-04-30 Tibotec Pharmaceuticals Makrociklički inhibitori virusa hepatitisa c
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
TWI393723B (zh) 2005-07-29 2013-04-21 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑（九）
EP2402331A1 (en) * 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
KR20140098867A (ko) 2005-11-11 2014-08-08 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 변이체
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
WO2008039794A1 (en) * 2006-09-25 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
ES2535212T3 (es) 2006-10-04 2015-05-06 Janssen Sciences Ireland Uc Carboxamido-4-[(4-piridil)amino]-pirimidinas para el tratamiento de la hepatitis C
ES2470568T3 (es) 2006-11-17 2014-06-24 Janssen R&D Ireland Inhibidores macroc�clicos del virus de la hepatitis C
PT2114924E (pt) * 2007-02-27 2012-04-03 Vertex Pharma Co-cristais e composições farmacêuticas que compreendem os mesmos
EP2134717A2 (en) * 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibitors of serine proteases
JP2010524970A (ja) * 2007-04-20 2010-07-22 デシフェラ ファーマシューティカルズ，エルエルシー 骨髄増殖性疾患及びその他の増殖性疾患の治療に有用なキナーゼ阻害剤
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
JP5443360B2 (ja) * 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
CA2710644C (en) 2007-12-24 2016-03-29 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis c virus inhibitors
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
AU2009281138B2 (en) 2008-08-14 2014-03-27 Tibotec Pharmaceuticals Macrocyclic indole derivatives useful as hepatitis C virus inhibitors
BRPI0922366B8 (pt) 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
SG171890A1 (en) 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
WO2010108187A2 (en) 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc FUSIONED CORE INHIBITORS OF HEPATITIS C
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
EP2528605A1 (en) 2010-01-29 2012-12-05 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
US9127010B2 (en) 2010-06-24 2015-09-08 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
AR082215A1 (es) 2010-07-14 2012-11-21 Vertex Pharma Composicion farmaceutica agradable al paladar
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
WO2012116370A1 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Methods and systems using pharmacokinetic and pharmacodynamic profiles in interferon-alpha therapeutic regimens
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
RU2014102102A (ru) 2011-06-23 2015-07-27 Дигна Байотек, С.Л. КОМПОЗИЦИЯ И КОМБИНИРОВАННЫЙ ПРЕПАРАТ ИНТЕРФЕРОНА-а5 С ИНТЕРФЕРОНОМ-а2 И СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
BR112014008616A2 (pt) 2011-10-10 2017-04-18 Hoffmann La Roche compostos antivirais
ES2564906T3 (es) 2011-12-16 2016-03-29 F. Hoffmann-La Roche Ag Inhibidores de NS5A del VHC
EP2794629B1 (en) 2011-12-20 2017-05-24 Riboscience LLC 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
AU2012357986B2 (en) 2011-12-20 2017-02-02 Riboscience Llc 4'-Azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
CN104203940B (zh) 2011-12-28 2017-01-18 爱尔兰詹森科学公司 作为hcv抑制剂的杂双环衍生物
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
KR20140130449A (ko) 2012-02-24 2014-11-10 에프. 호프만-라 로슈 아게 항바이러스 화합물
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
CN105073726B (zh) 2013-01-23 2017-05-31 弗·哈夫曼-拉罗切有限公司 抗病毒三唑衍生物
CN105008350B (zh) 2013-03-05 2018-05-08 弗·哈夫曼-拉罗切有限公司 抗病毒化合物
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
MA38678A1 (fr) 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
US9895442B2 (en) 2013-05-16 2018-02-20 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
AU2014339816B2 (en) 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
CN111194217B (zh) 2017-09-21 2024-01-12 里伯赛恩斯有限责任公司 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
AU2019242628A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
CN109970675A (zh) * 2018-05-28 2019-07-05 中国医学科学院医药生物技术研究所 一组硫脲化合物及其制备方法和应用
CA3100957A1 (en) 2018-06-19 2019-12-26 Novartis Ag N-substituted tetrahydrothienopyridine derivatives and uses thereof
WO2020123675A1 (en) * 2018-12-11 2020-06-18 Duke University Compositions and methods for the treatment of cancer
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CN110590535A (zh) * 2019-10-12 2019-12-20 重庆医药高等专科学校 用二氧化硒氧化芳香乙酮制备芳香乙醛酸的方法
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
US12076315B2 (en) 2020-03-20 2024-09-03 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171904A (en) 1965-10-21 1969-11-26 Unilever Ltd Anilinobenzimidazoles having Antibacterial Properties
IL39336A0 (en) 1971-05-04 1972-07-26 Lilly Co Eli Substituted 2-anilinobenzoxazoles
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994012184A1 (en) 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5444072A (en) 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives

Also Published As

Publication number Publication date
PL329639A1 (en) 1999-04-12
CN1219929A (zh) 1999-06-16
BG102945A (en) 1999-08-31
AP813A (en) 2000-02-28
AU723730B2 (en) 2000-09-07
EP0902782A1 (en) 1999-03-24
US20030195202A1 (en) 2003-10-16
SK286662B6 (sk) 2009-03-05
CZ298463B6 (cs) 2007-10-10
CZ338098A3 (cs) 1999-02-17
OA10902A (en) 2001-10-11
CA2252465A1 (en) 1997-10-30
CN1116288C (zh) 2003-07-30
CA2252465C (en) 2007-07-03
WO1997040028A1 (en) 1997-10-30
ID16664A (id) 1997-10-30
HUP0004421A2 (hu) 2001-04-28
SK146198A3 (en) 1999-07-12
IL126674A0 (en) 1999-08-17
NO984917L (no) 1998-12-23
NO312963B1 (no) 2002-07-22
CN1515248A (zh) 2004-07-28
US7329681B2 (en) 2008-02-12
US20050282876A1 (en) 2005-12-22
US6541496B1 (en) 2003-04-01
BR9708735A (pt) 1999-08-03
TR199802136T2 (xx) 2001-06-21
US6967214B2 (en) 2005-11-22
PL192628B1 (pl) 2006-11-30
NZ332405A (en) 2000-06-23
AP9700973A0 (en) 1997-07-31
AU2678597A (en) 1997-11-12
NO984917D0 (no) 1998-10-22
EA004771B1 (ru) 2004-08-26
IL126674A (en) 2005-08-31
BG64507B1 (bg) 2005-05-31
EA199800943A1 (ru) 1999-04-29
HUP0004421A3 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
IN190508B (OSRAM)
IN189791B (OSRAM)
IN192121B (OSRAM)
IN191982B (OSRAM)
ITMI960153A0 (OSRAM)
IN192622B (OSRAM)
IN191213B (OSRAM)
IN186913B (OSRAM)
IN186627B (OSRAM)
ITMI960463A0 (OSRAM)
IN185661B (OSRAM)
IN182350B (OSRAM)
BR9603859A (OSRAM)
ECSDI960312S (OSRAM)
CN3044348S (OSRAM)
CN3044170S (OSRAM)
CN3046158S (OSRAM)
CN3045911S (OSRAM)
CN3045888S (OSRAM)
CN3045880S (OSRAM)
CN3045853S (OSRAM)
CN3045694S (OSRAM)
CN3045208S (OSRAM)
CN3044349S (OSRAM)
CN3045530S (OSRAM)